Montag, 23. März 2026 · Earth Hour 20:30–21:30

The Daily

A curated briefing

Wien heute: Sunny +1°C (feels +0°C), ↖4km/h wind, 80% humidity, sunrise 05:51:45 sunset 18:10:28.

Biotech & Pharma

Earendil Labs raises $787M — a China-rooted “AI biotech” talks up a possible IPO

Endpoints reports that Earendil Labs has pulled in $787 million in financing as it gears up for what it frames as a possible IPO path. The company sits at the messy intersection of drug discovery, AI compute, and cross-border biotech capital — which means the story isn’t just “big round,” it’s also “how investable is the platform when geopolitics are the background radiation.” The hard part will be showing that the AI stack translates into clinical leverage (better hit rates, faster timelines), not just prettier charts. If they can point to concrete assets with clear endpoints (INDs / Phase 1 starts), the size of the raise stops being a curiosity and becomes a signal.
Source: Endpoints News

Novartis buys into mutant-selective PI3Kα: $2B upfront for SNV4818 (+$1B milestones)

Novartis agreed to acquire Synnovation’s subsidiary Pikavation to get SNV4818, a pan‑mutant‑selective PI3Kα inhibitor currently in Phase 1/2. The pitch is precision chemistry: hit mutant PI3Kα in tumor cells while sparing wild‑type PI3Kα in healthy tissue — aiming to fix the classic tolerability wall that has made PI3K inhibition hard to dose and harder to combine. Financially it’s a real bet: $2B upfront plus up to $1B in milestones, with closing expected in H1 2026. In HR+/HER2- breast cancer (where ~40% of tumors carry PIK3CA mutations), the strategic question is whether this enables earlier-line combinations with endocrine therapy and CDK inhibitors without the usual metabolic side-effect tax.
Source: Novartis

FDA clears “Wegovy HD” (7.2 mg semaglutide) via National Priority Voucher — filed-to-approval in 54 days

Pharmaphorum writes that the FDA approved a 7.2 mg Wegovy dose (to be marketed as Wegovy HD) as the fourth product through its National Priority Voucher pilot, with a 54‑day filing-to-approval timeline. The approval cites Novo Nordisk’s STEP UP trial: 20.7% mean weight loss (n≈1,400) versus 17.4% for the 2.4 mg dose, with comparable tolerability. Commercially, a higher-dose pen starting “next month” is less about squeezing a few extra points of efficacy and more about defending franchise depth as the GLP‑1 market gets crowded and payers get stricter. The policy angle is the real tell: the voucher program is now producing visible, fast approvals.
Source: Pharmaphorum

NBA

Wembanyama sends Spurs back to the playoffs: 101–100 game-winner vs Suns, 34/12 line

The Spurs clinched a playoff berth in the most cinematic way possible: Victor Wembanyama hit a go-ahead jumper with 1.1 seconds left to beat the Suns 101–100. He finished with 34 points and 12 rebounds (10-of-20 shooting) and San Antonio held Phoenix scoreless over the final 73 seconds. The bigger context is standings gravity: the win made it official after a surge (their fourth straight and 20th win in 22 games per the report), pushing them toward the top of the West rather than the play-in chaos. For the rest of the conference, the Spurs are no longer a “nice story” — they’re a bracket problem.
Source: Yahoo Sports

Suns stop the slide: 121–116 OT win vs Raptors behind Booker’s 34

Phoenix got a much-needed win, beating Toronto 121–116 in overtime with Devin Booker scoring 34. The shape of the game matters: OT wins like this often signal “we can still manufacture offense late,” even when the team isn’t crisp. For a Suns group trying to stabilize seeding, every close win that doesn’t turn into a fourth-quarter collapse is basically postseason practice. Toronto’s side of the story is the familiar one: competitive stretches, but not enough shot-making at the finish.
Source: AP News

AI & Tech

AI startups are eating venture — and the early returns (so far) look good

TechCrunch makes a blunt point: AI-native companies aren’t just another “hot sector” for VCs — they’re starting to internalize the venture function by scaling faster, compounding distribution, and converting capital into product velocity in ways that make classic stage-gating look slow. The practical implication is portfolio math: if AI startups can reach meaningful revenue (or defensible usage) earlier, the power-law shifts and mid-tier funds get squeezed. The hard detail that matters isn’t hype; it’s whether these companies keep margins once inference costs and compliance land. Watch the next 12 months for consolidation: the best founders will prefer fewer, deeper relationships — and everyone else will fight for scraps.
Source: TechCrunch

Report: Amazon is working on an Alexa-first smartphone (codename “Transformer”)

Amazon is reportedly exploring a new smartphone centered on Alexa — the kind of “assistant-native” hardware bet that keeps recurring every few years because the prize is huge: default distribution for the assistant layer. The question is whether 2026 is finally a moment where voice+agent workflows can feel less gimmicky, especially if Amazon can tie the device into Prime commerce and smart-home. The risk is also obvious: phones are brutally mature, and Fire Phone-style scars don’t fade. If this becomes real, expect it to be positioned more like a minimal, utility-first device than an iPhone killer.
Source: TechCrunch

OpenAI’s “superapp” plan: merge ChatGPT, Codex, and an Atlas browser into one desktop app

The Verge reports that OpenAI is working on a desktop “superapp” combining ChatGPT, the Codex coding product, and an Atlas AI-powered browser, citing a WSJ memo from Fidji Simo about reducing product fragmentation. This is a strategic tell: the company is betting that the winning interface is not “a chatbot tab,” but an OS-level work surface where chat, code, and browsing collapse into one. The competitive implication is direct: it’s a move into territory where Google and Microsoft already have home-field advantages. If OpenAI executes, it could also become a distribution wedge for agentic workflows that need browser control and code execution.
Source: The Verge

Travel

Rome starts charging for Trevi Fountain access: €2 entry, aiming for €6.5M/year

ROME (AP) — If you want the close-up Trevi Fountain moment, you now pay €2. The fee launched on a Monday as part of Rome’s overtourism management plan, alongside a €5 ticket fee for some city museums, with residents exempt. Officials estimate the Trevi policy could net about €6.5 million per year and improve flow in one of the city’s worst bottlenecks; the piazza view remains free, and after-hours access up close is still open. It’s a small number, but it’s psychologically big: Rome is testing the same “pay for prime-time access” logic that has already spread across Europe’s landmark economy.
Source: AP News

Brindisi als Base: römische Kolonnen, Hafen-Promenade, 6 km zum Flughafen — plus „panino col polpo“

Brindisi wird oft nur als „Tor zum Salento/Griechenland“ gesehen, aber die Stadt hat genug Substanz für einen eigenen Tag: Lungomare Regina Margherita, die römischen Kolonnen (Ende der Via Appia) und der Blick vom Monumento al Marinaio. Praktisch, wenn du mit Kids/Timing reist: der Flughafen liegt nur rund 6 km vom Zentrum entfernt, und vieles ist fußläufig. Kulinarisch ist das Ding hier nicht fancy, sondern ehrlich: frittura di pesce und das berühmte panino col polpo als schneller Hafen-Lunch. Wenn du Puglia im Frühling machst, ist Brindisi ein angenehmer, weniger überlaufener Startpunkt.
Source: visit.puglia.it

Science / Immuno-Oncology

Bridging radiation before CAR-T: meta-analysis (513 pts) suggests better response without higher CRS/ICANS

This Haematologica meta-analysis looks at radiation therapy as bridging before CAR-T in aggressive B-cell lymphoma. Across 10 studies and 513 patients, the pooled overall response rate after CAR-T was 79% (CR 56%) and the paper reports improved PFS / OS signals in those who received bridging RT. Importantly, safety didn’t obviously worsen: grade ≥3 CRS ~6% and grade ≥3 ICANS ~14% in the pooled analysis, with no clear signal of higher toxicity attributable to RT. The clinical takeaway is pragmatic: when disease control between leukapheresis and infusion is the gating factor, localized RT may be an underused lever — but it needs better prospective standardization (dose/fractionation, target selection).
Source: Haematologica

The cardiotoxicity problem in T-cell immunotherapies is becoming a first-class design constraint

A Nature Reviews Cardiology piece argues that cardiac events aren’t just “rare adverse events” anymore for potent T-cell therapies — they’re a mechanistic theme that has to be managed like CRS and neurotoxicity. The article synthesizes how cytokine-driven inflammation, on-target/off-tumor effects, and pre-existing cardiovascular risk can converge into arrhythmias, myocarditis, and hemodynamic instability, especially when patients are already fragile from prior lines. The implication isn’t to slow the field down; it’s to treat cardio monitoring and supportive care as part of the regimen design, not an afterthought. What I’d watch: trial protocols that bake in baseline echo/biomarkers and tighter early-cycle telemetry, because that’s how toxicity becomes predictable.
Source: Nature Reviews Cardiology

Wien – Kultur & Essen

Weekend-Preview Wien: Afterworks, Swap/Vintage, Pop-ups — die schnelle Route durch Do–So

Kurzliste: I LOVE OLD SCHOOL Afterwork · DECAF Afterwork x GAVIE · City Designquartier · Material Matters · Vintage Market Vienna · Clothing Swap. 1000things sammelt die Wochenend-Ideen in einem scannbaren Do–So-Format; perfekt, wenn du nur 5 Minuten hast, um „was machen wir?“ zu beantworten. Die Meta-Message: Wien ist gerade wieder im Modus „Frühling = raus“, mit vielen niedrigschwelligen, nicht-ticket-intensiven Formaten (Afterwork, Swap, Pop-up). Wenn du nur einen Fixpunkt willst: nimm einen Event als Anker und lass den Rest spontan im Grätzl passieren.
Source: 1000things

Wiener Kunstsupermarkt (Mariahilfer Straße): 95 Artists, 14 Länder, 5.000+ Werke — freier Eintritt (bis 28. März)

Der Kunstsupermarkt läuft noch bis 28. März 2026 — und das Format ist genau richtig, wenn man Kunst „low friction“ erleben will: Originale zu Fixpreisen, keine Galerie-Schwelle, keine Erklärungsangst. Laut wien.info zeigen rund 95 Kunstschaffende aus 14 Ländern über 5.000 Arbeiten (Zeichnungen, Aquarelle, Acryl/Öl, Fotoarbeiten, Kleinskulpturen). Für einen schnellen Wien-Nachmittag ist das ein sauberer Deal: gratis rein, 30–60 Minuten schauen, danach Kaffee/Spaziergang im 6./7. Bezirk.
Source: wien.info

Wien für Kinder

Earth Hour (23.3.) in Wien: 20:30–21:30 Licht aus — und ein Schattentheater als Familien-Ritual

Kurzliste: 20:30–21:30 Licht aus · Kerzen/„Dinner in the Dark“ · Schattentheater · Vorlagen/DIY-Figuren aus Karton · Fenster/Schachtel als Bühne. WIENXTRA macht aus der Earth Hour nicht „Verzicht“, sondern ein positives Familienformat: eine Stunde bewusst anders verbringen, ohne moralischen Zeigefinger. Praktisch sind die harten Zeiten (20:30–21:30) und die Idee, das Ganze über ein Schattenspiel zu gamifizieren, weil man als Elternteil nicht selbst auf der Bühne stehen muss („nur die Stimme“). Wenn du’s wirklich durchziehen willst: Figuren am Nachmittag vorbereiten, dann abends nur noch Lichtquelle + Leinwand.
Source: WIENXTRA

Frühling mit Kids in Wien: City Farm Augarten, Waldseilpark (ab 6.3.), Alpakas Oberlaa

Kurzliste: City Farm Augarten (Workshops) · Waldseilpark Kahlenberg (17 Parcours) · Motorikparks Donaustadt/Favoriten · Weghuberpark barrierefrei · Alpakas & Brillenschafe Oberlaa. 1000things bündelt Outdoor-Ideen, die genau in diese Übergangszeit passen: nicht „Ganztages-Ausflug“, sondern 2–3 Stunden mit klaren Zielen. Harte Details: der Waldseilpark hat laut Artikel ab 6. März 2026 geöffnet, bietet 17 Parcours bis 20 m Höhe; Kinder können ab 110 cm mitklettern (bis 14 mit Begleitperson). Für die Alltagslogistik ist das Gold, weil du schnell entscheiden kannst, ob’s „Klettern“, „Tiere“ oder „Spielplatz-Upgrade“ wird.
Source: 1000things